Efficacy Of Pramipexole For Non-motor Symptoms In Parkinson’s Diesase:A Meta-analysis

ObjectiveThis study through the meta analysis to pramipexole randomized controlled trials for the treatment of Parkinson’s disease, evaluates the efficacy and safety of pramipexole for non-motor symptoms of Parkinson’s disease, and provides effective evidence of evidence-based medicine for its clinical application. MethodsSearch out published literatures about pramipexole therapy of the non-motor symptoms of Parkinson’s disease during January 1997 to January 2016 using computer. Select standard literatures of high quality according to the into and exclusion criteria. Extract the available data after reading the full text. Do the Meta analysis for these clinical researches with Revman5.3 software, and calculate the odds ratio(OR)value, mean differences(MD), standard deviation(SD) and 95% confidence interval(95% CI), and test for Z. P < 0.05 is statistically significant in this research. ResultsParticipants included 13 references, the total sample size of 1862 cases, including pramipexole group of 924 cases, the control group of 938 cases. Do the meta-analysis respectively to the amplitude and the relative baseline of the UPDRS total scores, UPDRS part I total scores, HAMD scores, HAMA scores and the number of cases of UPDRS part I total scores improvement. The results show that UPDRS total scores, UPDRS part I total scores, HAMD scores and HAMA scores of the pramipexole group decrease obviously, and the number of cases of UPDRS total scores and UPDRS part I total scores improvement in pramipexole group increases obviously, and the difference is statistically significant(P<0.05). The results show that the overall efficacy of pramipexole for PD is exact, and pramipexole can alleviate the non-motor symptoms of spirit, behavior, emotions and relieve the PD with a state of depression and anxiety. The results of meta analysis of adverse reactions show that the incidence of dizziness, headache, insomnia, nausea, constipation and hypotension appearing in the course of medication in pramipexole group, has no statistically significant difference(P>0.05), which is compared with control group. Therefore, we can’t tell somebody that these adverse reactions cause by pramipexole. The incidence of illusion and movement disorders in pramipexole group is higher than the control group, and the difference is statistically significant(P<0.05). ConclusionThe treatment of Pramipexole for PD is curative effect, which can reduce UPDRSI part score, improve the non-motor symptoms of spirit, behavior, emotions. And the treatment of Pramipexole for PD associated with depression and anxiety state is curative effect. However at the same time, the incidence of illusion and movement disorders in the process of drug application is relatively higher than control group. How to use pramipexole safely and effectively still needs more higher quality evidence-based medical evidences for further guidance.